22 February 2021
Visiongain has published a new report on Antinuclear Antibody Test Market Report to 2031. According to the Visiongain analysis, the global antinuclear antibody test market is anticipated to grow at a CAGR of XX% during the forecast period (2021-2031). The global antinuclear antibody test market is segmented by product/services (reagents & assay kits, system, software & services), by application (rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome, scleroderma, other), by techniques (ELISA, immunofluorescence assay, multiplex assay, others), by end user (hospitals, clinical laboratories, others). By region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa). The report includes detailed profiles of leading antinuclear antibody test market players. PLUS COVID-19 Recovery Scenarios.
Global Antinuclear Antibody Test Market was valued at US$XX billion in 2021 and is projected to reach a market value of US$ XX billion by 2031. The study covers detailed and insightful chapters on market overview, market segments, new developments, competitive landscape, strategic recommendations, key company analysis, market opportunities, pricing analysis, gap analysis, porter’s 5 forces model, company profiling, geographical analysis, and analytical overview of the market. Increasing incidence of autoimmune diseases and supporting government initiatives are some of the factors driving the growth of Antinuclear Antibody Test market.
COVID-19 Impact on the Global Antinuclear Antibody Test Market
The COVID-19 pandemic negatively hit the antinuclear antibody test market due to the series of lockdown and stern social distancing rules across the globe. The global COVID-19 cases on 7th December 2020 were 67.5 million with 1.5 million fatalities, as per the Worldometers. There was complete halt in the production of the reagents & assay kits, system, software & services owing to the strict lockdowns in China, India, and other major countries of EU. Even after the unlocking of the global economies there was significant reduction in the ELISA, immunofluorescence assay, multiplex assay and other antinuclear antibody test in major hospitals, and clinical laboratories. Patients from around the globe have been performing antinuclear antibody test only in emergencies due to strict social distancing norms and fear of getting infected from the COVID-19. However, the success of the COVID-19 vaccines in the clinical trials and the positive sentiments around the globe, boosted the global antinuclear antibody test market.
Increasing prevalence of autoimmune diseases
The antinuclear antibody (ANA) test is a primary test to diagnose suspected autoimmune disorder. The ANA test may be positive or rule out different conditions with similar sign & symptoms. The patients with the autoimmune disorder systemic lupus erythematosus (SLE) are almost always positive for ANA, however, significant number of patients with other types of disorders may be positive for ANA. The increasing prevalence of autoimmune disorder may be due to various aspects of the environment which interrupt the balance of the immune system.
Rising Government Initiatives
The Autoimmune Diseases Coordinating Committee (ADCC) was established by the National Institutes of Health (NIH), directed by the National Institute of Allergy and Infectious Diseases (NIAID). The comprehensive research determines the causes of increasing prevalence. However, the government initiatives promote the development of improved diagnostic tools and evaluating effective strategies. The government initiatives, increasing concern about autoimmune diseases significantly boosts the global antinuclear antibody test market.
Increasing demand for Antinuclear Antibody Test.
The antinuclear antibody is blood test that looks at antinuclear antibodies (ANA). The antibodies produced by immune system bind to the body's own tissues. The screening test detects if such antibodies are present in the body. The increasing demand of antinuclear antibodies test to identify autoimmune disorder such as rheumatoid arthritis, Systemic Lupus Erythematosus, Sjögren’s Syndrome and many more. The prevalence of diseases and increasing awareness among population rises demand for antinuclear antibody test globally.
Bio-Rad Laboratories, Inc., Abbott Laboratories, Erba Diagnostics, Inc., Thermo Fisher Scientific, Inc., Trinity Biotech plc, Antibodies, Inc., EUROIMMUN AG, Inova Diagnostics, Seramun Diagnostic GmbH, Zeus Scientific, Inc., Merck KGaA are some of the key players contributing to the growth of the global antinuclear antibody test market. The market players are adopting various strategies to stay competitive in the global market such as new product developments, joint ventures, mergers and acquisitions, and geographical expansions.
In May 2019, Bio-Rad Laboratories, Inc. launched InteliQ, a range of quality controls offered in a tube configuration. It offers an effective data management and workflow, as it controls compatible with chemistry and immunoassay diagnostic platforms. The product enables to reduce manual errors, and time consumption.
In October 2020, Thermo Fisher Scientific received CE marking for its EliA SARS-CoV-2-Sp1 IgG test and its OmniPath COVID-19 Total Antibody ELISA Test for SARS-CoV-2. The test is designed for quantitative detection of immunoglobulin G against the virus.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Global liposomal drug delivery devices market is projected to grow at a CAGR of 10.69% by 2032.
21 June 2022
The global nanotechnology in drug delivery market was valued at US$53.0 billion in 2021 and is projected to grow at a CAGR of 18.7% during the forecast period 2022-2032.
20 June 2022
The global respiratory drug delivery technologies market was valued at US$59.51 billion in 2022 and is projected to grow at a CAGR of 7.31% during the forecast period 2022-2032.
15 June 2022
The global artificial intelligence (AI) in drug discovery market was valued at US$791 million in 2021 and is projected to grow at a CAGR of 30.7% during the forecast period 2022-2032.